Edesa Biotech, Inc. (EDSA) vs INmune Bio, Inc. (INMB)

Edesa Biotech, Inc. and INmune Bio, Inc. are both Biotechnology companies. Edesa Biotech, Inc. and INmune Bio, Inc. are of similar size ($55.5M and $54.5M). Edesa Biotech, Inc. grew revenue faster over the last twelve months: −43.5% against −51.6%. Across the 14 metrics below, INmune Bio, Inc. leads on 8 and Edesa Biotech, Inc. on 6.

Valuation

Metric EDSA INMB Biotechnology median
P/E n/m n/m 7.88
P/S 109.85 401.77 11.47
P/B 90.52 2.66 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 78.42 301.47 10.73
Earnings yield (42.14%) (33.00%) (28.84%)
Free cash flow yield (24.68%) (30.30%) (23.03%)

Profitability

Metric EDSA INMB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (531.32%) (74.82%) (57.72%)
Return on assets (102.46%) (57.08%) (49.22%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric EDSA INMB Biotechnology median
Revenue growth (TTM) (43.48%) (51.61%) 5.64%
EPS growth (last fiscal year) 34.20% 11.85% —
Revenue growth, 5-year CAGR (15.40%) 35.37% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EDSA INMB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.76 4.04 4.73
Net debt to EBITDA 1.39 0.52 0.96

Dividend

Metric EDSA INMB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric EDSA INMB Biotechnology median
Market cap 54.45m 55.51m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack